WSJ : Board Practices Hurt Banco Popular, Experts Say

Board Practices Hurt Banco Popular, Experts Say
The problems at the Spanish lender went beyond the bank run that forced a European Central Bank rescue

When Europe’s central bank orchestrated an overnight rescue of Banco Popular Español SA in June, the immediate spark was a bank run that left the Spanish lender close to collapse.

But Banco Popular’s problems ran deeper, touching an area that has been devilishly difficult for European regulators to address: poor governance.

The bank’s problems, governance experts say, included board members who weren’t independent enough from management and deals with companies that had ties to the board.

Corporate governance shortcomings are more common in European banks compared with the U.S., experts say. Some attribute the difference to a fragmented continent where countries’ capital markets are in varied stages of development and have different rules and regulations.

“In Europe, you have 28 different banking systems, which were created nationally under different mandates,” said Tom Kirchmaier, deputy director of corporate governance at the London School of Economics.

Since the European Central Bank assumed supervision of major eurozone banks in November 2014, it has stepped up the focus on corporate governance, pressing lenders, for instance, to ensure boards include a sufficient number of independent directors. Since then, the ECB conducted 94 on-site visits to examine governance issues, the second-highest number of inspections after loan risk.

When the ECB began to regulate Banco Popular, Spain’s No. 6 lender by assets, it inherited a bank that analysts say was riddled with governance problems.

In its 2016 annual report, the bank said seven of 15 board members were independent. However, four had longstanding links to Banco Popular, ties that governance experts say undermined their ability to challenge executives’ decisions.

One had served as finance director and chief executive at the bank immediately before becoming a board member. Governance experts say there should be at least a few-years’ “cooling off” period for a director in that situation to be considered independent.

Another member sat on the board for nearly 10 years, a duration governance experts consider too long to be deemed independent.

A third filled in for her father when he stepped down from the board after serving for more than two decades.

A fourth previously had been a nonindependent director representing an investor who remained a significant shareholder.

A Banco Popular spokeswoman said Spain’s securities regulator reviewed and had no objection to the bank’s designation of the board members as independent. A board member can be considered independent for up to 12 years under Spanish law, she noted.

Analysts say that coziness between the board and management contributed to the board’s slowness to remove Ángel Ron as executive chairman, despite investor concern the bank wasn’t doing enough to shed roughly €37 billion in sour loans. Mr. Ron was replaced in December after 12 years at the helm and more than a 90% drop in the bank’s share price.

The bank spokeswoman declined to comment on Mr. Ron’s departure.

Mr. Ron has said the liquidity problems that ultimately triggered Banco Popular’s takeover began after he stepped down, according to people familiar with his reasoning.

“Truly independent board members are key to avoid conflicts of interest that end up impacting stakeholders,” said Carlos García, an analyst with financial services firm Kepler Cheuvreux SA. ”Popular is an example of why governance matters.”

Another issue for Banco Popular was its relationships with firms that had representation on its board.

For example, on June 2 French lender Banque Fédérative du Crédit Mutuel SA, which had one seat on the board, nearly doubled to 100% its stake in a retail bank it managed with Banco Popular. The same day, the French lender’s representative stepped down from the board of the bank. Five days later, Banco Popular was rescued and sold to Spain’s Banco Santander SA for a token €1.

Mr. Kirchmaier said unless the purchase of the stake was ordered by regulators amid the resolution process—which remains unclear—the move raises questions about whether Crédit Mutuel used information garnered in its board capacity to do the deal.

Representatives for Crédit Mutuel declined to comment.

A spokesman for Spain’s market regulator said the ties between Crédit Mutuel and Banco Popular were disclosed and detailed to investors in the bank’s annual reports.

A Banco Popular spokeswoman declined to comment on corporate governance issues. The ECB declined to comment on specific cases.

Banco Popular’s board members also approved deals that made it appear the bank was on sounder financial footing than it was, according to analysts.

In mid-2014, as Banco Popular was struggling to recover from Spain’s financial crisis, the bank sold the rights to the future profits generated by some of its insurance and pension products. The buyer was a newly created firm managed by a sole administrator who was also an employee of Banco Popular, according to the bank’s 2014 and 2015 annual reports.

Banco Popular booked a €97 million profit from the sale.

The bank had also financed 48% of the deal, according to its annual reports. That means Banco Popular was financing its own profits.

That approach can mask the true value of a transaction and is often done when a company is in financial trouble, said James Shein, a professor and corporate governance expert at Northwestern University’s Kellogg School of Management.

“Almost 100% of time there are bank failures, first there was a governance problem,” Mr. Shein said.

Banco Popular said in its annual reports that the deal was done at arm’s length and evaluated by an independent expert.

The bank’s spokeswoman declined to comment.

>>> Oncor to swap assets with Sharyland Utilities in USD 400m deal

Oncor to swap assets with Sharyland Utilities in USD 400m deal
24 JUL 2017
Oncor Electric Delivery Company LLC, a Dallas, Texas-based electricity distributor and transmission provider, will swap distribution assets and customer accounts with Sharyland Utilities, L.P., an Amarillo, Texas-based public utility, in a USD 400m transaction.
In the transaction, SDTS will receive 258 miles of 345 kV transmission lines from Oncor, and Oncor will receive Sharyland's distribution network and retail delivery customers.
This transaction allows Oncor to acquire new customers and continue to expand its service territory.
Oncor Electric Delivery operates the largest distribution and transmission system in Texas, delivering power to more than 3.4 million homes and businesses and operating more than 122,000 miles of transmission and distribution lines in Texas.

FT : Mitsubishi Tanabe to pay $1.1bn for Israeli drugmaker

Mitsubishi Tanabe to pay $1.1bn for Israeli drugmaker
Nasdaq-listed Neuroderm is testing a treatment for Parkinsons

Mitsubishi Tanabe Pharma became the latest Japanese company to target the US’s $450bn drug market by agreeing a $1.1bn takeover of a US-listed Israeli group that is testing a treatment for Parkinson’s disease.

The Japanese company announced it would pay $39 in cash per share to acquire NeuroDerm. The transaction has an enterprise value of a little over $1bn after accounting for NeuroDerm’s excess cash position, or $1.1bn including advisory costs.

Mitsubishi Tanabe, which hopes to establish a franchise around neurological and autoimmune diseases, will separately make its first foray into the US next month with the launch of a treatment for motor neurone disease.

Globally, Japan’s drug market is second only to the US, but the deal is one of an increasing number by Japanese companies trying to diversify away from the domestic market where the government’s sweeping review to make drug prices more affordable to the country’s ageing population threatens earnings. It also represents part of the broader demand for overseas growth that drove foreign acquisitions by Japanese buyers to a record ¥10.9tn ($97.9bn) in the fiscal year ended March 31.

If completed, the NeuroDerm deal would be the third-biggest outbound Japanese drug acquisition this year behind Takeda Pharmaceuticals’ $5.2bn purchase in January of Boston-based cancer drugmaker Ariad, and Sawai Pharmaceuticals buying generics maker Upsher-Smith Laboratories for $1.05bn.

The offer from Mitsubishi Tanabe, which has a market capitalisation of ¥1.49tn, represents a 17.5 per cent premium to NeuroDerm’s closing price on July 21, but a 79 per cent premium to its close on June 9 before media reports that the Tel Aviv-based company was considering a sale.

“We believe that this transaction will yield important benefits for NeuroDerm’s shareholders and the Parkinson’s disease patients that urgently need new therapies,” said Oded Lieberman, NeuroDerm’s chief executive.

The Japanese drugmaker generated ‎¥‎22.7bn, or a little more than 5 per cent of total revenue, from overseas sales in the fiscal year ended March 31 and hopes the NeuroDerm deal will “enable” it to achieve its US sales target of ‎¥‎80bn by the end of its 2020 fiscal year.

“The model used by pharmaceutical manufacturers has been to cover their fixed costs in the Japanese domestic market and to earn profits in overseas markets, with the US as the main target. We expect the shift in focus to overseas markets to gather momentum,” noted Fumiyoshi Sakai, an analyst at Credit Suisse.

NeuroDerm, which had 77 employees as of March, will become the sole entity within Mitsubishi Tanabe’s Israel-established subsidiary, which would make it a wholly-owned subsidiary of the Japanese company in a so-called reverse triangular merger.

Mitsubishi Tanabe said it had secured the support of three of NeuroDerm’s directors who collectively own 33.7 per cent of the company’s stock.

The deal, which is subject to shareholder approval, would be one of the biggest in Israeli corporate history. Earlier this year tech giant Intel bought Mobileye, a developer of self-driving car technologies, for $15.3bn, the largest takeover in Israeli history.

Shares in Mitsubishi Tanabe Pharma closed 1.2 per cent lower in Tokyo on Monday, a little more than double the decline for the broader Japanese stock market. Shares in Neuroderm shot up 15 per cent in premarket New York trading to just below $39.

FT : China’s HNA reveals ownership details after US stake transfer

China’s HNA reveals ownership details after US stake transfer
Non-profit foundation has taken the 29.5 per cent of company held by mysterious shareholder

HNA Group, the ultra-acquisitive Chinese conglomerate, has transferred ownership of a near 30 per cent stake in the business away from a mysterious Chinese shareholder to a newly formed foundation in the US.

The disclosure came as part of the first detailed breakdown of privately held HNA’s ownership structure after a period of intense scrutiny of the company, which has garnered attention for an aggressive overseas $40bn deal spree in the past three years.

In a statement, HNA said that a non-profit organisation called the Hainan Cihang Charity Foundation now owned 29.5 per cent of the company — a stake that was until recently held by Guan Jun, who acquired the position last year from Hong Kong-based businessman Bharat Bhise.

The Chinese company confirmed to the FT that Mr Guan, who serves as a co-chairman of a peer-to-peer financing platform owned by the Chinese group, no longer held any shares in the company. It added that the foundation that holds his stake was created in New York in December 2016 and only recently took control of Mr Guan’s shareholding.

The group, which started as a small domestic Chinese airline, has been forced to repeatedly deny allegations by an exiled businessman, Guo Wengui, that the family of Wang Qishan, one China’s most powerful politicians and the man who has led the country’s crackdown on corruption, has benefited from hidden ties to the company.

The speculation has also been fuelled by HNA’s continued ability to strike deals since the start of the year, including the purchase of a near 10 per cent stake in Deutsche Bank, even as other previously prolific, private Chinese conglomerates have seen their overseas dealmaking ambitions crimped by new domestic regulations.

When reached by mobile phone last month to discuss his investment in HNA, Mr Guan told the FT: “It is inconvenient to answer of any of your questions.” He could not be reached on Monday.

HNA’s unwieldy dealmaking spree has resulted in a complex corporate structure. It owns $145bn in assets, which it claims generate more than $90bn in annual revenues and employ more than 400,000 people. Its stakes are held across a range of industries from asset management and financial services to aviation and logistics.

The company has also sought politically connected partners. It invested in a fuel shipping business with Jeb Bush, when the son of a former US president was considering a presidential run, and it has agreed to buy SkyBridge Capital, a fund that invests in hedge funds, from its founder Anthony Scaramucci, who was just appointed as the communications director for the Trump administration.

On Monday, HNA also confirmed other details relating to its other major investors, which were previously revealed in the FT. Hainan Province Cihang Foundation, which is incorporated in China, owns 22.8 per cent of the business.

Chen Feng, HNA’s founder, and Wang Jian, its chairman, each own just under 15 per cent of the business. A further 10 individuals who are either executives or directors at the company hold the remainder of the company, comprised of stakes of no greater than 4 per cent.

“Although we are a private company with no obligation to disclose our ownership, we respect and appreciate the desire for transparency in this regard,” HNA said in a statement, adding that it planned to provide annual updates about its structure.

HNA said that the Cihang Foundation was created to further its philanthropic vision and that all shareholders pledged to donate all their shares to the foundation upon their resignation or death.

“These equity commitments not only provide a stable source of capital for the Foundation’s charitable work but also reflect our strong belief that wealth should be earned, not inherited, to encourage personal and public achievements,” HNA said. “We expect that the Cihang Foundation will one day own 100% of HNA Group. That has always been our intention.”

>>> US Arconic beats by $0.06, beats on revs; raises FY17 EPS and revs guidance,

Arconic beats by $0.06, beats on revs; raises FY17 EPS and revs guidance, in-line
  • Reports Q2 (Jun) earnings of $0.32 per share, excluding non-recurring items, $0.06 better than the Capital IQ Consensus of $0.26; revenues rose 0.8% year/year to $3.26 bln vs the $3.18 bln Capital IQ Consensus
    • All segments delivered higher volumes while maintaining focus on cost reduction savings. Annualized return on net assets was 8.7% based on the results of the first half of 2017.
  • Co raised guidance for FY17, sees EPS of $1.15-1.20, excluding non-recurring items, vs. $1.16 Capital IQ Consensus Estimate, from $1.10-1.20; raises FY17 revs guidance to $12.3-12.7 bln vs. $12.43 bln Capital IQ Consensus Estimate, up from $11.8-12.4 bln.

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
:
  • PETS +3.7%, PHG +3.3%, VFC +2.3%, HAL +2%,
M&A news:
  • WBMD +19.7% (confirms agreement to be acquired by KKR (KKR) for $66.50/share in cash)
  • NDRM +15.5% (NeuroDerm to be acquired by Mitsubishi Tanabe Pharma for $39.00 per share)
Other news:
  • DRYS +11.1% (rebounding following Friday's weakness)
  • OCN +4.8% (to transfer its interest in mortgage servicing rights and subservicing relating to approx. $110 billion UPB of non-agency MSRs to New Residential Investment (NRZ); in conjunction, NRZ has agreed to make an equity investment of approx. $13.9 mln to purchase approx. 4.9% of Ocwen's common equity), .
Analyst comments:
  • DOVA +1.5% (downgraded to Underweight at First Analysis Sec)
  • CAT +0.7% (upgraded to Outperform at BMO Capital Markets)

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
:
  • HIBB -15.7%, HAS -4.9%, CALM -3.4%, RPM -3.1%, RYAAY -2.9%, TERP-2%, SILC -0.6%, SWK -0.5%
Other news:
  • BPMX -14.1% (discloses entry into Securities Purchase Agreement to sell an aggregate of 5.5 mln shares of common stock at a price of $0.36/share)
  • TEAR -7.2% (pulling back following Friday's strength)
  • RDUS -3.4% (confirms the CHMP issued a second Day-180 List of Outstanding Issues and requested additional data analyses related to the safety and efficacy of abaloparatide-SC)
  • SRPT -1.9% (offering to sell $250 mln in shares of its common stock in an underwritten public offering)
  • PLUG -0.8% (modestly pulling back following Friday's advance)
Analyst comments:
  • CBI -1.7% (downgraded to Neutral from Outperform at Credit Suisse)
  • ATHN -1.3% (downgraded to Underweight at First Analysis Sec)
  • STZ -1.3% (downgraded to Neutral at Goldman; Removed from Conviction Buy List)
  • GS -0.5% (downgraded to Neutral from Buy at UBS)

>>> Lennox Int'l beats by $0.07, beats on revs; guides FY17 EPS in-line, revs in

Lennox Int'l beats by $0.07, beats on revs; guides FY17 EPS in-line, revs in-line
  • Reports Q2 (Jun) earnings of $2.83 per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus of $2.76; revenues rose 8.1% year/year to $1.10 bln vs the $1.09 bln Capital IQ Consensus.
  • Co issues in-line guidance for FY17, sees EPS of $7.75-8.15, excluding non-recurring items, vs. $7.95 Capital IQ Consensus Estimate and vs prior guidance of $7.55-8.15; sees FY17 revenue growth of +4-7%, up from prior guidance of +3-7%; the new guidance computes as $3.79-3.90 bln vs. $3.84 bln Capital IQ Consensus Estimate.
  • "In our Residential business, revenue was up 14% on strength in both replacement and new construction business. Segment margin expanded 130 basis points to 21.5%, and segment profit rose 21%. Our Residential business set new all-time highs for revenue, segment margin and profit. In our Commercial business, we have seen lumpy customer demand and mix in the first half of the year. After a record [Q1] with strong growth in revenue, margin, and profit, Commercial revenue was up 3% at constant currency in [Q2], with segment margin of 17.3% down 140 basis points."
  • Looking ahead to 2H17, co expects Commercial revenue, margin and profit to be up from the prior-year period.
  • Looking ahead for the company overall, co continues to expect strong growth for a year of record revenue and profit, led by the strength in its Residential business. Given the company's first-half performance and outlook for 2H17, co is raising the low end of its 2017 guidance for revenue and adjusted EPS.